|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
3
|
Zhang J, Song Z, Zhang Y, Zhang C, Xue Q,
Zhang G and Tan F: Recent advances in biomarkers for predicting the
efficacy of immunotherapy in non-small cell lung cancer. Front
Immunol. 16:15548712025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe
Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha
R, Pluzanski A, et al: Five-year survival outcomes with nivolumab
plus ipilimumab versus chemotherapy as first-line treatment for
metastatic non-small-cell lung cancer in CheckMate 227. J Clin
Oncol. 41:1200–1212. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Chen T, Nie TY, Han J, He Y, Tang X
and Zhang L: Hyperprogressive disease in non-small cell lung cancer
after PD-1/PD-L1 inhibitors immunotherapy: Underlying killer. Front
Immunol. 14:12008752023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giurini EF, Pappas SG and Gupta KH: Sweet
surprises: Decoding tumor-associated glycosylation in cancer
progression and therapeutic potential. Cells. 15:2332026.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee T, Teng TZJ and Shelat VG:
Carbohydrate antigen 19-9-tumor marker: Past, present, and future.
World J Gastrointest Surg. 12:468–490. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Islam MK, Khan M, Gidwani K, Witwer KW,
Lamminmäki U and Leivo J: Lectins as potential tools for cancer
biomarker discovery from extracellular vesicles. Biomark Res.
11:852023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren X, Lin S, Guan F and Kang H:
Glycosylation targeting: A paradigm shift in cancer immunotherapy.
Int J Biol Sci. 20:2607–2621. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oh YJ, Dent MW, Freels AR, Zhou Q,
Lebrilla CB, Merchant ML and Matoba N: Antitumor activity of a
lectibody targeting cancer-associated high-mannose glycans. Mol
Ther. 30:1523–1535. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smolarz B, Durczyński A, Romanowicz H,
Szyłło K and Hogendorf P: miRNAs in cancer (review of literature).
Int J Mol Sci. 23:28052022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cánovas-Cervera I, Nacher-Sendra E, Suay
G, Lahoz A, García-Giménez JL and Mena-Mollá S: Role of miRNAs as
epigenetic regulators of immune checkpoints in lung cancer
immunity. Int Rev Cell Mol Biol. 390:109–139. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato Y, Okuyama S and Hori K: Primary
structure and carbohydrate binding specificity of a potent anti-HIV
lectin isolated from the filamentous cyanobacterium Oscillatoria
agardhii. J Biol Chem. 282:11021–11029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamamoto M, Harada Y, Suzuki T, Fukushige
T, Yamakuchi M, Kanekura T, Dohmae N, Hori K and Maruyama I:
Application of high-mannose-type glycan-specific lectin from
Oscillatoria agardhii for affinity isolation of tumor-derived
extracellular vesicles. Anal Biochem. 580:21–29. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng XX, Yu R, Wu X, Wu SY, Pi C, Chen ZH,
Zhang XC, Gao CY, Shao YW, Liu L, et al: Correlation of plasma
exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK
wild-type advanced non-small cell lung cancer. J Immunother Cancer.
8:e0003762020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Costa C, Indovina P, Mattioli E, Forte IM,
Iannuzzi CA, Luzzi L, Bellan C, De Summa S, Bucci E, Di Marzo D, et
al: P53-regulated miR-320a targets PDL1 and is downregulated in
malignant mesothelioma. Cell Death Dis. 11:7482020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yokobori T, Yazawa S, Asao T, Nakazawa N,
Mogi A, Sano R, Kuwano H, Kaira K and Shirabe K: Fucosylated
α1-acid glycoprotein as a biomarker to predict prognosis following
tumor immunotherapy of patients with lung cancer. Sci Rep.
9:145032019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakayama S, Umeda M, Kobayashi K, Nakano
Y, Hori K, Umemura T and Kurokawa H: MicroRNAs in circulating
extracellular vesicles as biomarkers of early colorectal cancer
captured using high-mannose N-glycan-specific lectin from
Oscillatoria agardhii. Front Oncol. 15:16194602025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakazawa N, Yokobori T, Kaira K, Turtoi A,
Baatar S, Gombodorj N, Handa T, Tsukagoshi M, Ubukata Y, Kimura A,
et al: High stromal TGFBI in lung cancer and intratumoral
CD8-positive T cells were associated with poor prognosis and
therapeutic resistance to immune checkpoint inhibitors. Ann Surg
Oncol. 27:933–942. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuriyama K, Yokobori T, Sohda M, Nakazawa
N, Yajima T, Naruse I, Kuwano H, Shirabe K, Kaira K and Saeki H:
Plasma Plastin-3: A tumor marker in patients with non-small-cell
lung cancer treated with nivolumab. Oncol Lett.
21:112021.PubMed/NCBI
|
|
22
|
Kaira K, Higuchi T, Naruse I, Arisaka Y,
Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, et al:
Metabolic activity by 18F-FDG-PET/CT is predictive of early
response after nivolumab in previously treated NSCLC. Eur J Nucl
Med Mol Imaging. 45:56–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoruker EE, Terzioglu D, Teksoz S, Uslu
FE, Gezer U and Dalay N: MicroRNA expression profiles in papillary
thyroid carcinoma, benign thyroid nodules and healthy controls. J
Cancer. 7:803–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McDermott AM, Kerin MJ and Miller N:
Identification and validation of miRNAs as endogenous controls for
RQ-PCR in blood specimens for breast cancer studies. PLoS One.
8:e837182013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dezfuli NK, Alipoor SD, Dalil Roofchayee
N, Seyfi S, Salimi B, Adcock IM and Mortaz E: Evaluation expression
of miR-146a and miR-155 in non-small-cell lung cancer patients.
Front Oncol. 11:7156772021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Monastirioti A, Papadaki C, Kalapanida D,
Rounis K, Michaelidou K, Papadaki MA, Mavroudis D and Agelaki S:
Plasma-based microRNA expression analysis in advanced stage NSCLC
patients treated with nivolumab. Cancers (Basel). 14:47392022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chatterjee S, Ugonotti J, Lee LY,
Everest-Dass A, Kawahara R and Thaysen-Andersen M: Trends in
oligomannosylation and α1,2-mannosidase expression in human
cancers. Oncotarget. 12:2188–2205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruhaak LR, Taylor SL, Stroble C, Nguyen
UT, Parker EA, Song T, Lebrilla CB, Rom WN, Pass H, Kim K, et al:
Differential N-glycosylation patterns in lung adenocarcinoma
tissue. J Proteome Res. 14:4538–4549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lattova E, Skrickova J, Hausnerova J,
Krystofova K, Zdrahal Z, Kren L and Popovic M: N-glycans in lung
tissue specimens: A prospective target for enhanced cancer
diagnosis and prognosis. J Transl Med. 23:9182025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato Y, Murakami M, Miyazawa K and Hori K:
Purification and characterization of a novel lectin from a
freshwater cyanobacterium, Oscillatoria agardhii. Comp Biochem
Physiol B Biochem Mol Biol. 125:169–177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ,
Lu ZY, Fang YC, Chen XF and Liu GT: The prognostic value of PD-L1
expression for non-small cell lung cancer patients: A
meta-analysis. Eur J Surg Oncol. 41:450–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khandelwal A, Sharma U, Barwal TS, Seam
RK, Gupta M, Rana MK, Vasquez KM and Jain A: Circulating miR-320a
acts as a tumor suppressor and prognostic factor in non-small cell
lung cancer. Front Oncol. 11:6454752021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yadav R, Khatkar R, Yap KC, Kang CY, Lyu
J, Singh RK, Mandal S, Mohanta A, Lam HY, Okina E, et al: The miRNA
and PD-1/PD-L1 signaling axis: An arsenal of immunotherapeutic
targets against lung cancer. Cell Death Discov. 10:4142024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Izadifard M, Ahmadvand M, Chahardouli B,
Vaezi M, Janbabai G, Seghatoleslami G, Bahrami M, Yaghmaie M and
Barkhordar M: Plasma-circulating miR-638, miR-6511b-5p,
miR-3613-5p, miR-455-3p, miR-5787, and miR-548a-3p as noninvasive
biomarkers of immune reconstitution post-allogeneic hematopoietic
stem cell transplantation in acute myeloid leukemia patients.
Transpl Immunol. 91:1022402025. View Article : Google Scholar : PubMed/NCBI
|
